Cutting-edge Research Unveiled at NKF’s Annual Professional Meeting
- 19 abr 2021
- 1 min de lectura
© 2021 National Kidney Foundation, Inc.
Hundreds of studies from the last year were presented including three studies considered “late-breaking” research papers. The late-breaking research presented today included a study of RenalytixAI’s new prognostic blood test that will make it easier to diagnosis early kidney disease in patients with type 2 diabetes; a study that demonstrated the safety and tolerability of Metformin as a potential therapeutic intervention in autosomal dominant polycystic kidney disease; and a study that shows that patients on dialysis are more willing than the general population to accept the COVID-19 vaccine.
Comentarios